Conference Coverage

How to beat apremilast-induced diarrhea


 

EXPERT ANALYSIS FROM RWCS 2016

References

He reported serving on scientific advisory boards for, and/or as a consultant to, nine pharmaceutical companies.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

NNTs show once-unimaginable psoriasis outcomes now readily attainable
MDedge Dermatology
Subclinical inflammation predicts progression from psoriasis to PsA
MDedge Dermatology
Expert advises how to use shingles vaccine in rheumatology patients
MDedge Dermatology
Brodalumab met primary endpoints, deaths called ‘unrelated’
MDedge Dermatology
Minimal disease activity criteria in PsA fall short
MDedge Dermatology
60 weeks of ixekizumab effective, well tolerated in moderate-to-severe plaque psoriasis
MDedge Dermatology
Don’t overlook topical tazarotene for psoriasis
MDedge Dermatology
Fresh evidence of methotrexate efficacy in psoriatic arthritis
MDedge Dermatology
Sparse, poor evidence supports fumarates for psoriasis
MDedge Dermatology
Ixekizumab approved for plaque psoriasis
MDedge Dermatology